Table 2.
Genotypes Identified
| All (N=9,589) | European American, not Hispanic (N=6,986) | African American, not Hispanic (N=953) | PREDICT preemptive model target population (N=5,764)ˆ | |
|---|---|---|---|---|
|
| ||||
| CYP2C19 | ||||
| rs4244285 (*2) heterozygote | 2,398 (25%) | 1,751 (25%) | 235 (25%) | 1,431 (25%) |
| rs4244285 (*2) homozygote* | 238 (2%) | 170 (2%) | 25 (3%) | 123 (2%) |
| rs4986893 (*3) heterozygote | 14 (0%) | 2 (0%) | 1 (0%) | 3 (0%) |
| rs4986893 (*3) homozygote | 2 (0%) | 0 | 0 | 1 (0%) |
| rs28399504 (*4) heterozygote | 46 (0%) | 36 (1%) | 1 (0%) | 26 (0%) |
| rs28399504 (*4) homozygote | 0 | 0 | 0 | 0 |
| rs56337013 (*5) heterozygote | 1 (0%) | 1 (0%) | 0 | 1 (0%) |
| rs56337013 (*5) homozygote | 0 | 0 | 0 | 0 |
| rs72552267 (*6) heterozygote | 6 (0%) | 5 (0%) | 1 (0%) | 4 (0%) |
| rs72552267 (*6) homozygote | 0 | 0 | 0 | 0 |
| rs41291556 (*8) heterozygote | 52 (1%) | 44 (1%) | 1 (0%) | 34 (1%) |
| rs41291556 (*8) homozygote | 1 (0%) | 1 (0%) | 0 | 0 |
|
| ||||
| SLCO1B1 | ||||
| rs4149056 (*5) heterozygote | 2,279 (24%) | 1,805 (26%) | 66 (7%) | 1,346 (23%) |
| rs4149056 (*5) homozygote* | 181 (2%) | 147 (2%) | 3 (0%) | 104 (2%) |
|
| ||||
| CYP2C9 | ||||
| rs1799853 (*2) heterozygote | 1,998 (21%) | 1,622 (23%) | 42 (4%) | 1,229 (21%) |
| rs1799853 (*2) homozygote | 156 (2%) | 129 (2%) | 1 (0%) | 92 (2%) |
| rs1057910 (*3) heterozygote | 1,046 (11%) | 831 (12%) | 31 (3%) | 644 (11%) |
| rs1057910 (*3) homozygote* | 29 (0%) | 23 (0%) | 1 (0%) | 14 (0%) |
|
| ||||
| VKORC1 | ||||
| rs9923231 heterozygote | 4,170 (43%) | 3,305 (47%) | 182 (19%) | 2,507 (43%) |
| rs9923231 homozygote | 1,185 (12%) | 943 (13%) | 10 (1%) | 687 (12%) |
|
| ||||
| TPMT | ||||
| rs1800462 (*2) heterozygote | 52 (1%) | 44 (1%) | 2 (0%) | 32 (1%) |
| rs1800462 (*2) homozygote* | 0 | 0 | 0 | 0 |
| rs1800460 (*3B) heterozygote | 1 (0%) | 0 | 0 | 0 |
| rs1800460 (*3B) homozygote* | 0 | 0 | 0 | 0 |
| rs1142345 (*3C) heterozygote | 171 (2%) | 68 (1%) | 81 (8%) | 107 (2%) |
| rs1142345 (*3C) homozygote* | 2 (0%) | 0 | 2 (0%) | 2 (0%) |
| rs1800460+rs1142545 (*3A, 3D, 3E) heterozygote | 649 (7%) | 514 (7%) | 20 (2%) | 380 (7%) |
| rs1800460+rs1142545 (*3A, 3D, 3E) homozygote* | 9 (0%) | 6 (0%) | 0 | 4 (0%) |
|
| ||||
| CYP3A5 | ||||
| rs776746 (*3) heterozygote | 1,663 (17%) | 918 (13%) | 402 (42%) | 1,003 (17%) |
| rs776746 (*3) homozygote | 7,332 (76%) | 6,022 (86%) | 98 (10%) | 4,357 (76%) |
*
High risk genotype (not all-inclusive, as compound heterozygosity for TPMT variants also high-risk)
ˆ
PREDICT preemptive model target population, including those with history of coronary artery stent and/or with PREDICT risk score > 40, indicating a 40% likelihood of exposure to clopidogrel, warfarin or a statin over 3 years